Phillips recalled the HeartStart MRx monitor/defibrillator after discovering electrical and battery connection issues that could prevent the device from powering up, charging and delivering an electrical shock therapy.

Older adults with atrial fibrillation who underwent left atrial appendage occlusion (LAAO) at the time of cardiac surgery had an approximately 40 percent reduction in thromboembolism and a 15 percent reduction in all-cause mortality, according to a database analysis.

Levosimendan, a drug used to prevent heart failure during heart surgery, was shown to not reduce adverse outcomes in patients at a high risk for low cardiac output syndrome in a new study debuted at the American College of Cardiology’s 66th Annual Scientific Session.

BioSig Technologies announced an agreement to work with two Mayo Clinic cardiac electrophysiologists to develop features and applications for the company’s PURE EP system.

Patients with atrial fibrillation and at least one additional risk factor for stroke who received digoxin had higher mortality rates compared with those who did not take digoxin, according to an analysis of a randomized trial.

New results on Abbott Vascular’s Absorb everolimus-eluting bioresorbable vascular scaffold (BVS) were revealed at this year’s American College of Cardiology (ACC)’s Scientific Session, providing disappointing results for the stent that are consistent with a trend set by previous studies.

Subclinical leaflet thrombosis occurred in 13.6 percent of patients undergoing transcatheter aortic valve replacement (TAVR) and 3.8 percent of patients undergoing surgical aortic valve replacement (SAVR), according to an analysis of two registries.

The FDA approved the CoreValve Evolut PRO valve for transcatheter aortic valve replacement (TAVR) in patients with severe, symptomatic aortic stenosis who are at high or extreme risk for open heart surgery.